Title:
SELECTION METHOD OF CHEMOTHERAPY FOR STOMACH CANCER PATIENT WHICH CONSISTS OF COMBINATION DRUG OF TEGAFUR/GIMERACIL/OTERACIL POTASSIUM AND EGFR INHIBITOR
Document Type and Number:
Japanese Patent JP2016128473
Kind Code:
A
Abstract:
PROBLEM TO BE SOLVED: To provide chemotherapy that exerts strong life prolongation effect for stomach cancer patients, and has little adverse effect.SOLUTION: A method for predicting therapeutic effect of chemotherapy using a combination drug of tegafur/gimeracil/oteracil potassium in a stomach cancer patient includes the following processes (1) to (3): (1) a process of measuring an expression amount of EGFR containing in a biological sample collected from the patient; (2) a process of comparing the expression amount of EGFR obtained in the process (1) with a preset corresponding cut-off point; and (3) a process of, in the case where the expression amount of EGFR is higher than the cut-off point as a result of the comparison in the process (2), predicting it is highly likely to show sufficient therapeutic effect in order to select chemotherapy using the combination drug of tegafur/gimeracil/oteracil potassium and EGFR inhibitor in combination for the patient, and, in the case where the expression amount of EGFR is the cut-off point or less, predicting it is highly likely to show sufficient therapeutic effect in order to select chemotherapy using a combination drug of tegafur/gimeracil/oteracil potassium for the patient independently.SELECTED DRAWING: None
Inventors:
OBUNAI TAKASHI
SAITO HITOSHI
TAKECHI TEIJI
SAITO HITOSHI
TAKECHI TEIJI
Application Number:
JP2016013066A
Publication Date:
July 14, 2016
Filing Date:
January 27, 2016
Export Citation:
Assignee:
TAIHO PHARMACEUTICAL CO LTD
International Classes:
A61K31/53; A61K31/4412; A61K31/513; A61K39/395; A61P35/00; A61P43/00; G01N33/50; G01N33/68
Foreign References:
| WO2010074240A1 | 2010-07-01 | |||
| WO2008035461A1 | 2008-03-27 |
Other References:
JPN6015042976; Ｓ-Ｗ Ｈａｎ: 'Ｐｈａｓｅ ＩＩ ｓｔｕｄｙ ａｎｄ ｂｉｏｍａｒｋｅｒ ａｎａｌｙｓｉｓ ｏｆ ｃｅｔｕｘｉｍａｂ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ｍｏｄｉｆｉｅｄ ＦＯＬＦＯＸ６ ｉｎ ａｄｖａｎｃｅｄ ｇａｓｔｒｉ' Ｂｒｉｔｉｓｈ Ｊｏｕｒｎａｌ ｏｆ Ｃａｎｃｅｒ Ｖｏｌ．１００， Ｎｏ．２, 2009, Ｐａｇｅ．２９８-３０４
JPN6012034937; 保坂洋夫等: '新薬・プロフィールファイル〔１２〕アービタックス 注射液１００ｍｇ' 週刊薬事新報 Ｎｏ．２５９５， Ｐａｇｅ．１０００-１００４, 2009
JPN6015042973; Ｉｇｏｒ Ｓｉｒａｋ: 'Ｅｐｉｄｅｒｍａｌ Ｇｒｏｗｔｈ Ｆａｃｔｏｒ Ｒｅｃｅｐｔｏｒ ａｓ ａ Ｐｒｅｄｉｃｔｏｒ ｏｆ Ｔｕｍｏｒ Ｒｅｓｐｏｎｓｅ ｔｏ Ｐｒｅｏｐｅｒａｔｉｖｅ Ｃｈｅｍｏｒａｄｉａｔｉｏｎ ｉｎ' Ｓｔｒａｈｌｅｎｔｈｅｒ Ｏｎｋｏｌ Ｖｏｌ．１８４， Ｎｏ，１１, 2008, Ｐａｇｅ．５９２-５９７
JPN6012034937; 保坂洋夫等: '新薬・プロフィールファイル〔１２〕アービタックス 注射液１００ｍｇ' 週刊薬事新報 Ｎｏ．２５９５， Ｐａｇｅ．１０００-１００４, 2009
JPN6015042973; Ｉｇｏｒ Ｓｉｒａｋ: 'Ｅｐｉｄｅｒｍａｌ Ｇｒｏｗｔｈ Ｆａｃｔｏｒ Ｒｅｃｅｐｔｏｒ ａｓ ａ Ｐｒｅｄｉｃｔｏｒ ｏｆ Ｔｕｍｏｒ Ｒｅｓｐｏｎｓｅ ｔｏ Ｐｒｅｏｐｅｒａｔｉｖｅ Ｃｈｅｍｏｒａｄｉａｔｉｏｎ ｉｎ' Ｓｔｒａｈｌｅｎｔｈｅｒ Ｏｎｋｏｌ Ｖｏｌ．１８４， Ｎｏ，１１, 2008, Ｐａｇｅ．５９２-５９７
Attorney, Agent or Firm:
Patent Business Corporation Saegusa International Patent Office
Previous Patent: Fatty acid amide hydrolase inhibitor
Next Patent: A method for using anti-CD100 antibody and this
Next Patent: A method for using anti-CD100 antibody and this